Evidence map›Paper›PMID 19881343›Full record

ReviewCurrent opinion in gastroenterology2010

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Hoonmo L Koo, Herbert L DuPont

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07791940 (Evaluation of the Role of Rifaximin on Thrombocytopenia in Patients With Hepatitis C-Related Liver Cirrhosis), which is not on this map. Cited by 63 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 4 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07791940 phase4completednot on this mapstarted 2015, after this paper: background citation

Evaluation of the Role of Rifaximin on Thrombocytopenia in Patients With Hepatitis C-Related Liver Cirrhosis

TypeinterventionalSponsorFayoum University HospitalRan2015 to 2016Enrolled165ConditionsThrombocytopenia Related to Chronic Liver DiseaseArmsRifaximin (drug), Rifaximin Placebo
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 4 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Impact of the BioFireBMC infectious diseases · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Management of severe and fulminantJournal of medical microbiology · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Hoonmo L KooBaylor College of Medicine, Houston, Texas 77030, USA. koo@bcm.tmc.edu
Herbert L DuPont
Baylor College of Medicine · USNational Center for Infectious Diseases · US

Funding

Host Genetic Susceptibility and Immune Responses to Norovirus InfectionsK23DK084513 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI KOO, HOONMO LEE · 2009 to 2012
$699k
NIDDK NIH HHS 1K23DK084513-01NIDDK NIH HHS K23 DK084513
6 · The paper itself

Abstract

purpose of reviewRifaximin is gaining attention for its potential activity in a multitude of gastrointestinal diseases. We review the unique pharmaceutical properties of this antibiotic and the published evidence in the literature regarding the use of rifaximin for different gastrointestinal disorders. RECENT

findingsRifaximin is a gastrointestinal-selective antibiotic with a broad spectrum of antimicrobial activity, an excellent safety profile, minimal drug interactions, and negligible impact on the intestinal microbiome. Rifaximin is currently approved in the United States for the treatment of travelers' diarrhea caused by noninvasive diarrheagenic Escherichia coli and is approved in more than 30 other countries for a variety of gastrointestinal disorders. Considerable research with this medication has been conducted for the treatment and prevention of travelers' diarrhea, the treatment of portal systemic encephalopathy, Clostridium difficile infection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, pouchitis, and colonic diverticular disease. SUMMARY: Rifaximin is effective for the treatment of travelers' diarrhea and can be considered as the treatment of choice for uncomplicated travelers' diarrhea. When invasive travelers' diarrhea pathogens are suspected, an alternative antibiotic should be administered. Rifaximin appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatment of portal systemic encephalopathy. This antibiotic may be effective for other gastrointestinal diseases, but more well designed clinical studies are needed to confirm its efficacy for these off-label indications. Future studies will determine whether the development of significant bacterial resistance will limit rifaximin use.

Indexed as

TravelAnti-Infective AgentsBacterial InfectionsDose-Response Relationship, DrugDrug Administration ScheduleDysenteryFemaleFollow-Up StudiesGastroenteritisHumansMaleRandomized Controlled Trials as TopicRifamycinsRifaximinRisk AssessmentTreatment OutcomeAnti-Infective AgentsRifamycinsRifaximin

Identifiers

PMID19881343
PMCPMC4737517
OpenAlexW2121076704

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.